Loading...
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on in...
Saved in:
| Published in: | Chin Med J (Engl) |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Wolters Kluwer Health
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7213629/ https://ncbi.nlm.nih.gov/pubmed/32265426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000745 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|